MicroRNAs in cancer: personalizing diagnosis and therapy
MicroRNAs in cancer: personalizing diagnosis and therapy
复制标题
DOI：
10.1111/j.1749-6632.2010.05822.x
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Croce, Carlo M.
中科院分区：
文献类型：
--
作者：
Nana-Sinkam, S. Patrick;Fabbri, Muller;Croce, Carlo M.
MicroRNAs(MiRNAs)是一种19-24nt的非编码RNA，与实体肿瘤和血液系统恶性肿瘤的发病机制有关。MiRNAs通常位于脆弱的染色体区域，对细胞分化、凋亡和生长等关键生物学功能至关重要。MiRNAs既可以作为肿瘤抑制因子，也可以作为癌基因。因此，它们有可能同时作为癌症的生物标记物和治疗剂。根据我们在最近于2010年5月19-21日在西班牙巴塞罗那举行的走向个性化癌症医学会议上的报告，我们概述了miRNA去调控在实体和血液系统恶性肿瘤中的当前知识及其作为疾病生物标记物的应用。
MicroRNAs (miRNAs) are 19-24nt noncoding RNAs that have been implicated in the pathogenesis of both solid and hematological malignancies. Frequently located in fragile chromosomal regions, miRNAs are essential to key biological functions, such as cellular differentiation, apoptosis, and growth. miRNAs may serve as either tumor suppressors or oncogenes. As a result, they have the potential to serve as both biomarkers and therapeutic agents in cancer. Based on our presentation at the recent Towards Personalized Cancer Medicine conference held in Barcelona, Spain, May 19-21, 2010, we provide an overview of the current knowledge of miRNA deregulation in solid and hematological malignancies and their application as biomarkers of disease.